INmune Bio (INMB) Earnings Analysis

INmune Bio (INMB) next reports earnings on 2026-08-06, consensus EPS -0.20667 USD. Last quarter (2026-05-07) it beat with EPS -0.2 USD vs -0.245 USD est (+18.4%). It has beaten estimates in 4/5 recent quarters (80%). Trailing P/E -1.09.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does INMB next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate-0.20667 USD
Revenue estimate0.00B

INMB earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-07-0.2 USD-0.245 USD+18.4%Beat
2026-03-30-0.18 USD-0.27 USD+33.3%Beat
2025-10-30-0.24 USD-0.31 USD+22.6%Beat
2024-10-31-0.6 USD-0.49 USD-22.4%Miss
2024-08-01-0.5 USD-0.63 USD+20.6%Beat

Beat rate: 4/5 (80%) over reported quarters with consensus data.

INMB valuation and analyst view

Trailing P/E-1.09
Trailing EPS-1.56481 USD
Price / book2.49
Dividend yield0.00%
Market cap0.05B
Analyst consensusBuy (6 buy / 2 hold / 1 sell)

Related research pages

Frequently asked questions

When is INmune Bio (INMB)'s next earnings date?

INmune Bio is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.20667 USD and revenue estimate of 0.00B.

Did INMB beat earnings last quarter?

In its 2026-05-07 report, INMB posted EPS of -0.2 USD versus a -0.245 USD estimate — a beat of 18.4%.

What is INMB's earnings track record?

Over the last 5 reported quarters with consensus data, INMB beat estimates 4 times (80%).

What is INMB's current P/E ratio and EPS?

INMB trades at a trailing P/E of -1.09 on trailing EPS of -1.5648146051469578 USD.

What do analysts rate INMB?

Analyst consensus is "Buy" across 9 ratings (0 strong buy, 6 buy, 2 hold, 1 sell, 0 strong sell).